logo
  

Sempra Energy To Sell Solar Assets To Consolidated Edison For $1.54 Bln

Sempra Energy (SRE) Thursday said it has agreed to sell its U.S. non-utility operating solar assets, solar and battery storage development projects and one wind facility to Consolidated Edison Inc. (ED) for $1.54 billion in cash.

"This sale represents an important step forward in the portfolio-optimization plan we announced in June to support market growth opportunities," said Joseph Householder, president and chief operating officer of Sempra Energy. "We plan to work closely with Consolidated Edison to ensure a smooth transition."

On June 28, Sempra Energy announced a multi-phase, portfolio-optimization initiative designed to sharpen the company's strategic focus and create value for all shareholders.

Sempra Energy said intends to sell the rest of its non-utility U.S. wind and certain U.S. midstream natural gas assets.

The assets included in the sale to Consolidated Edison are-- Mesquite Solar 2 and 3 in Arizona; Copper Mountain Solar 1 and 4 in Nevada; Great Valley Solar in California; and solar and battery storage development projects.

The sale is expected to be completed near the end of 2018. The sale is subject to customary closing conditions, including approvals of the Federal Energy Regulatory Commission and the U.S. Department of Energy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT